TABLE 2.
Patient characteristics according to the received treatment
| Atezolizumab cohort (n = 600), No. (%) | Docetaxel cohort (n = 575), No. (%) | χ2 test p‐value | |
|---|---|---|---|
| Age | |||
|
•Median (range), years •≥65 years •<65 years |
63 (25–84) 271 (45.2) 329 (54.8) |
64 (34–85) 264 (45.9) 311 (54.1) |
.7974 |
| Smoking status | |||
|
•Former/current •Never |
493 (82.2) 107 (17.8) |
487 (84.7) 88 (15.3) |
.2443 |
| Sex | |||
|
•Male •Female |
372 (62.0) 228 (38.0) |
357 (62.1) 218 (37.9) |
.9755 |
| ECOG PS | |||
|
•0 •1 |
216 (36.0) 384 (64.0) |
215 (37.4) 360 (62.6) |
.6210 |
| Histological type | |||
|
•Squamous •Nonsquamous |
158 (26.3) 442 (73.7) |
157 (27.3) 418 (72.7) |
.7073 |
| No. of metastatic sites | |||
|
•≤2 •>2 |
270 (45.0) 330 (55.0) |
230 (40.0) 345 (60.0) |
.0833 |
| No. of prior therapies | |||
|
•1 •2 |
457 (76.2) 143 (23.8) |
433 (75.3) 142 (24.7) |
.7304 |
| PD‐L1 expression | |||
|
•Positive (TC1/TC2/TC3 and/or IC1/IC2/IC3) •Negative •Unknown |
340 (57.2) 254 (42.8) 6 |
255 (44.6) 317 (55.4) 3 |
.5313 |
| EGFR mutation | |||
|
•Negative •Positive •Unknown |
444 (74.0) 59 (9.8) 97 (16.2) |
435 (75.7) 48 (8.3) 92 (16.0) |
.6624 |
| EML4‐ALK translocation | |||
|
•Negative •Positive •Unknown |
306 (51.0) 4 (0.7) 290 (48.3) |
264 (45.9) 1 (0.2) 310 (53.9) |
.0808 |
| KRAS mutation | |||
|
•Negative •Positive •Unknown |
147 (24.5) 39 (6.5) 414 (69.0) |
125 (21.7) 44 (7.7) 406 (70.6) |
.4432 |
| NLR | |||
|
•Median (IQR) •≥4 •<4 |
3.9 (2.5–5.8) 289 (48.2) 311 (51.8) |
4.3 (2.7–8.2) 306 (53.2) 269 (46.8) |
.0836 |
Abbreviations: ALK, anaplastic lymphoma kinase; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; IC, immune cells; IQR, interquartile range; NLR, neutrophil to lymphocyte ratio; PD‐L1, programmed death ligand 1; PS, performance status; TC, tumor cells.